Wellington Management Group LLP Raises Stock Holdings in QIAGEN N.V. $QGEN

Key Points

• Wellington Management Group LLP has increased its holdings in Qiagen N.V. by 12.2%, owning approximately 10.99% of the company, with a value of about $972 million.
• Qiagen's stock received mixed ratings from analysts, with some downgrading it to a "buy" rating and others issuing hold ratings, reflecting a current average target price of $49.69.
• In the last reported quarter, Qiagen posted a $0.60 earnings per share and revenue of approximately $533.54 million, indicating a year-over-year revenue growth of 7.7%.

Wellington Management Group LLP increased its position in QIAGEN N.V. (NYSE:QGEN - Free Report) by 12.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,438,441 shares of the company's stock after buying an additional 2,656,136 shares during the quarter. Wellington Management Group LLP owned 10.99% of QIAGEN worth $972,191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC bought a new stake in QIAGEN in the 4th quarter worth approximately $202,000. Wells Fargo & Company MN lifted its position in QIAGEN by 31.8% in the 4th quarter. Wells Fargo & Company MN now owns 66,779 shares of the company's stock worth $2,974,000 after buying an additional 16,106 shares during the last quarter. GAMMA Investing LLC increased its stake in QIAGEN by 93.9% in the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares during the period. Cetera Investment Advisers increased its stake in QIAGEN by 23.2% in the 1st quarter. Cetera Investment Advisers now owns 13,917 shares of the company's stock worth $551,000 after purchasing an additional 2,620 shares during the period. Finally, LPL Financial LLC increased its stake in QIAGEN by 2.6% in the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after purchasing an additional 432 shares during the period. Institutional investors own 70.00% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cowen reaffirmed a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Bank of America lifted their price target on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Wall Street Zen cut QIAGEN from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. UBS Group lifted their price target on QIAGEN from $48.00 to $50.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Finally, Barclays assumed coverage on QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $49.69.

QIAGEN Trading Up 1.2%

Shares of QGEN traded up $0.5840 during mid-day trading on Friday, hitting $49.7140. 882,883 shares of the company's stock traded hands, compared to its average volume of 1,336,129. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. QIAGEN N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The firm has a market capitalization of $11.05 billion, a P/E ratio of 29.37, a PEG ratio of 2.61 and a beta of 0.64. The business's 50-day moving average price is $48.61 and its 200-day moving average price is $43.90.

QIAGEN (NYSE:QGEN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.60. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. During the same period in the previous year, the firm earned $0.55 earnings per share. The business's revenue was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, sell-side analysts forecast that QIAGEN N.V. will post 2.26 EPS for the current fiscal year.

QIAGEN Announces Dividend

The company also recently declared a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were paid a $0.25 dividend. This represents a yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. QIAGEN's dividend payout ratio is presently 14.79%.

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.